Citius Pharmaceuticals, Inc. - Common Stock (NQ:CTXR)

0.9292 +0.0812 (+9.58%)

Streaming Delayed Price Updated: 3:39 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Citius Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 18, 2023

Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+...

Via Benzinga

Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket ↗

January 18, 2023

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) rose 41.5% to $0.3255 in pre-market trading after gaining 8% on Tuesday.

Via Benzinga

Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm ↗

May 25, 2022

Via Benzinga

Citius Pharmaceuticals (NASDAQ: CTXR) Spearheads the Global Cancer Immunotherapy Market

May 07, 2022

Via Get News

Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial ↗

April 06, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 26, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 23, 2022

Via Benzinga

Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket ↗

October 17, 2022

Gainers

Via Benzinga

11 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 23, 2022

Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million.

Via Benzinga

Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings ↗

September 23, 2022

Via Benzinga

Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket ↗

August 11, 2022

Gainers

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

August 11, 2022

Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch!

Via InvestorPlace

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 22, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

June 07, 2022

Gainers

Via Benzinga

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is Specializing in Stem Cell Therapy & Critical Cancer Care Immunotherapy

May 11, 2022

Via Get News

3 Reddit Stocks to Buy in May ↗

May 08, 2022

Via InvestorPlace

Citius Pharmaceuticals, Inc is helping Global Cancer Immunotherapy to reach the Market Cap of 152 Billion by 2024.

May 04, 2022

Via AB Newswire

The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)

May 04, 2022

Via Viz Release

61 Biggest Movers From Yesterday ↗

April 28, 2022

Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with...

Via Benzinga

First Patient Dosed in Citius Pharma's Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids ↗

April 26, 2022

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced enrolment of first patient in the Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 06, 2022

Gainers Healthcare Triangle (NASDAQ:HCTI) stock moved upwards by 17.5% to $1.35 during Wednesday's pre-market session. The company's market cap stands at $47.6...

Via Benzinga

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 17, 2022

Gainers Rhythm Pharmaceuticals (NASDAQ:RYTM) stock increased by 16.4% to $7.72 during Thursday's regular session. The current volume of 639.5K shares is 152.7% of...

Via Benzinga

Penny Stock Watchlist - Here Are My Five Top Picks ↗

February 17, 2022

If you got into Amazon at the start of 2021, by the end of 2021 you'd have made about 73% gains. Not bad for a year. It's impressive until you consider that one of these stocks made 258% gains in the...

Via Talk Markets

FDA Signs Off Citius Pharma's Phase 2 Trial With Halo-Lido In Hemorrhoids ↗

February 15, 2022

The FDA has issued a Study May Proceed letter for Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Halo-Lido to treat hemorrhoids. The Company anticipates...

Via Benzinga

Citius Pharmaceuticals: Q1 Earnings Insights ↗

February 10, 2022

Citius Pharmaceuticals (NASDAQ:CTXR) reported its Q1 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Citius...

Via Benzinga

Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential ↗

September 10, 2021

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Via Benzinga

Citius Pharmaceuticals Addresses Unmet Needs for Patients with CVCs ↗

August 04, 2021

Image by falco from Pixabay What happens when the one product keeping you alive becomes infected? Central venous catheters (CVCs) are important life lines for treating many...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021 ↗

November 30, 2021

Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ:

Via Benzinga

Could Citius Pharmaceuticals Be a Millionaire-Maker Stock? ↗

July 20, 2021

A lot would have to go right for this biotech to make investors rich.

Via The Motley Fool

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.